Penn Medicine, Intel to deploy innovative AI approach to identify brain tumors

  • Perelman School of Medicine is working with Intel to advance a new distributed machine learning technique.

  • The technique allows for researchers at disparate organizations around the world to work together to develop new deep learning initiatives without having to share data.

  • The research will be trained on the largest brain tumor dataset to date, without identifiable patient data leaving the individual collaborators.


Perelman School of Medicine at the University of Pennsylvania is working with Intel to advance a new distributed machine learning technique – one that allows for researchers at disparate organizations around the world to work together to develop new deep learning initiatives without having to share data.
 

WHY IT MATTERS

That approach, which aims for big advances in collaborative AI research while still maintaining patient privacy, is called federated learning.

Researchers at Penn Medicine have published findings that a federated-learning approach to medical-imaging AI could train a model to more than 99% of the accuracy of a model trained in the traditional, non-private method.
 

Read More: CMS announced an increase in inpatient rates, new hospital payment category for CAR T


So Penn is working with 29 research institutions from the U.S. – as well as in Canada, the U.K., Germany, the Netherlands, Switzerland and India – using Intel technology to deploy a federated-learning approach to develop new deep learning models for identifying brain tumors.

n order to train and build a model to detect a brain tumor that could aid in early detection and better outcomes, these researchers need access to large amounts of relevant medical data. By using federated learning, they will be able to work together on building and training an algorithm to detect a brain tumor while protecting sensitive medical data.

Penn Medicine and Intel say the research will be trained on the largest brain tumor dataset to date, without identifiable patient data leaving the individual collaborators.
 

THE LARGER TREND

Even if more evidence is needed, AI and machine learning are proving their worth in the field of medical imaging. In April, for instance, a study on AI-augmented diabetic retinopathy screening indicated that such programs are cheaper than human grading – that a deep learning system would save on the roughly two minutes of human labor required to grade each case.

The Penn Medicine and Intel initiative is funded by a three-year, $1.2 million grant from the Informatics Technology for Cancer Research program of the National Institutes of Health.


Read More: Prescryptive Health and Bartell Drugs Team up to Expand Access to Reliable and Secure COVID-19 Antibody Testing


Some of the collaborating institutions planning to participate in the first phase of this federation are the Hospital of the University of Pennsylvania, Washington University in St. Louis, the University of Pittsburgh Medical Center, Vanderbilt University, Queen's University, Technical University of Munich, University of Bern, King's College London and Tata Memorial Hospital.
 

ON THE RECORD


It is widely accepted by our scientific community that machine learning training requires ample and diverse data that no single institution can hold, this year, the federation will begin developing algorithms that identify brain tumors from a greatly expanded version of the International Brain Tumor Segmentation challenge dataset. This federation will allow medical researchers access to vastly greater amounts of healthcare data while protecting the security of that data.

- Dr. Spyridon Bakas at Penn's Center for Biomedical Image Computing and Analytics.


AI shows great promise for the early detection of brain tumors, but it will require more data than any single medical center holds to reach its full potential, Using Intel software and hardware and support from some of Intel Labs’ brightest minds, we are working with the University of Pennsylvania and a federation of 29 collaborating medical centers to advance the identification of brain tumors while protecting sensitive patient data.

- Jason Martin, principal engineer at Intel Labs.


About Penn Medicine

Penn Medicine’s mission is to advance knowledge and improve health through research, patient care, and the education of trainees in an inclusive culture that embraces diversity, fosters innovation, stimulates critical thinking, supports lifelong learning, and sustains our legacy of excellence. Penn Medicine includes six acute-care hospitals and hundreds of outpatient centers throughout the region. Our hospitals include The Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Pennsylvania Hospital, Chester County Hospital, Lancaster General Health and Penn Medicine Princeton Health.


About Intel

Intel is a technology leader focused on unleashing the potential of data so that we can fulfill our purpose: Create world-changing technology that enriches the lives of every person on earth. This is our ultimate motivation and why we exist. We are in the midst of an exciting journey to go beyond just PCs and servers to a company that is at the center of a new era where everything looks and acts like a computer. The explosion of devices and data has led to several technology inflections—AI, 5G network transformation, and the rise of the intelligent edge—that, together

Spotlight

Other News
Health Technology

Rudolf Riester GmbH Announces Global Market Launch of Telemedicine Solution, Showcases ri-sonic® E-Stethoscope + eMurmur® AI Integration

Rudolf Riester GmbH | January 29, 2024

Rudolf Riester GmbH, a global leader in medical technology, proudly announces the full market launch of its comprehensive Telemedicine offering. Already in active use across Europe, the Middle East, and Africa, the solution from the trusted Riester brand delivers industry-leading quality and versatility through integration of a broad range of medical devices to meet the needs of diverse user scenarios. "Since its founding 75 years ago, Riester has been a pioneer in providing accurate and efficient diagnostic devices for front-line healthcare. We have brought this passion and expertise to the creation of our telemedicine solution," said Dr. Georgiana Gasquères, Global Business Unit Director, Telemedicine at Riester. "Now we empower healthcare providers worldwide with the tools they need to deliver accurate diagnosis and exceptional care to every patient, everywhere, and to do it more sustainably." Riester is demonstrating its Telemedicine Case and Cart offerings at the Arab Health show in Dubai, 29 January – 1 February 2024, at booth SA.E30. Traveling nurses with South African healthcare innovator EQiGate are already evaluating dozens of patients every week with the Riester Telemedicine Case. "EQiGate selected the Riester Telemedicine solution for its high quality, comprehensiveness, and versatile, Windows-based compatibility with our portfolio of operating applications," stated Braam Kruger, CEO at EQiGate. "The Riester solution integrates seamlessly with our Hospital at Home concept, enabling us to bring the hospital to the patient, a healthcare paradigm shift that yields significant cost and time savings for both the healthcare system and the patient." At Arab Health, Riester is showcasing the integration of their industry-leading ri-sonic® E-stethoscope with the eMurmur® AI platform. Digital auscultation with ri-sonic and eMurmur AI enables the early detection and analysis of heart murmurs, informing better, more timely decisions about treatment pathways. To demonstrate their commitment to raising heart health awareness and improving quality of life through accurate and efficient diagnosis, Riester is offering complimentary advisory heart checks to all exhibition attendees at their booth at Arab Health, conducted by a professional cardiologist. "Our participation at Arab Health reaches beyond showcasing our technological advancements; it is about educating and engaging with the public – including Arab Health attendees – and healthcare professionals," said Irina Zhdanova, CEO of Riester. "By providing free advisory heart checks, we emphasise the significance of regular cardiac health assessments and demonstrate how innovative technology can be a pivotal tool in advancing diagnostic cardiac care to improve health outcomes. This is a perfect way to honor Riester’s 75-year heritage and act on our vision and mission." About Rudolf Riester GmbH Since its founding in Germany in 1948, Rudolf Riester GmbH has been a pioneering force in improving quality of life through accurate and efficient diagnosis on the front-line of healthcare. By developing and manufacturing high-quality, market-leading medical diagnostic products, Riester has earned a global reputation for quality, reliability, and innovation in the healthcare sector, with a presence in over 150 countries. Specializing in diagnostic devices, Riester's product portfolio includes telemedicine solutions as well as stethoscopes, blood pressure monitors, otoscopes, ophthalmoscopes, and other medical equipment. Riester is part of the Halma plc group of companies.

Read More

Medical Devices

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Medtronic | January 08, 2024

Medtronic plc a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors. The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024. Medtronic will begin the phased commercial launch in Europe in the summer of 2024. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor. The MiniMed™ 780G system is Medtronic's most advanced insulin delivery system, automatically adjusting and correcting† glucose levels every 5 minutes.§ It's the world's only system with a Meal Detection™ feature‡ that is designed to reduce post-meal hyperglycemia when users occasionally forget to give themselves insulin or underestimate the number of carbs in their snacks or meal. The system, which is available with the world's only 7-day infusion set, also features one of the lowest glucose target settings (as low as 100 mg/dL) of any automated insulin delivery system. With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes. With both Simplera Sync™ sensor and the Guardian™ 4 sensor, no fingersticks are required. "A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugars (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children," Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences "With its responsive algorithm, the MiniMed™ 780G system can help people living with diabetes even when they occasionally forget to bolus or undercount their carbs. The system takes on more of the work involved in diabetes management and helps alleviate mental burden." "We're incredibly proud that the MiniMed™ 780G system continues to be the most widely used automated insulin delivery system in Europe since we launched it in 2020. Real-world data on over 100,000 users on the system across many geographies and cultures shows that when using recommended settings the system is delivering an average Time in Range of nearly 80%, raising the bar on what 'good' looks like2," said Que Dallara, EVP and President, Medtronic Diabetes. "With the introduction of Simplera Sync™ sensor, we're able to offer the proven benefits of our MiniMed™ 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds." The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for ages 7+ and compatible with iOS and Android. Simplera Sync™ sensor is not approved by the FDA and is limited to investigational use in the U.S. Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. The Simplera™ CGM for integrated use with the InPen™ smart insulin pen received CE Mark in September 2023. About the Diabetes Business at Medtronic Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More

Digital Healthcare

Syra Health Wraps Up a Successful 2023, including New Contracts, Contract Extensions, and the introduction of new Healthcare Innovations

Syra Health | January 04, 2024

Syra Health Corp. a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, is excited to summarize its significant accomplishments and the introduction of its innovative solutions across the Company's six business units. Within its Behavioral and Mental Health Business Unit, Syra Health Launched Syrenity, the Company's flagship mental and behavioral product, focused on preventing mental health crises. Syrenity is evidence-based and AI-backed, offering continual monitoring and cognitive therapy interventions. Syrenity also integrates with telehealth, allowing for easy access to licensed mental health professionals when treatment is necessary. Entered into a strategic agreement with E&I Cooperative Services (E&I) which extended Syrenity's reach to over 6,000 colleges and universities nationwide, that make up E&I's membership. Secured a five-year, $4.75 million contract with the District of Columbia's Department of Behavioral Health, to support vital mental health programs in communities. Entered into a one-year agreement with the County of Camden Psychological Screening and Evaluation Services to provide mental health screening and evaluations to Camden County, New Jersey law enforcement personnel. Received a contract from the Mississippi Department of Human Services (MDHS) to provide behavioral and mental health services to the Oakley Youth Development Center and other locations as directed by MDHS. Across its Digital Health Business Unit, Syra Health Launched CarePlus, an easy-to-use, secure, and scalable electronic medical record (EMR) system for small and mid-sized healthcare organizations. CarePlus is affordable and accessible by simplifying clinical workflows, integrating labs, radiology, and telehealth. Unveiled SyraBot, a digital health product that uses human-centric AI to deliver conversational and immediate responses to inquiries made through any healthcare organization's website. SyraBot provides real-time access to information users need, twenty-four hours a day, seven days a week in up to 200 languages. As part of its Population Health Business Unit, Syra Health Received a two-year contract extension, worth up to $636,000 with the Indiana Division of Mental Health and Addiction and Family and Social Services Administration, to chair and manage the State of Indiana's Epidemiological Outcomes Workgroup. Secured a five-year contract worth $275,000 with the City of San Antonio to evaluate its Racial and Ethnic Approaches to Community Health (REACH) Healthy Neighborhoods Project. Across its Health Education Business Unit, Syra Health Entered into a new strategic agreement with the Maricopa County Department of Public Health in Arizona where Syra Health experts trained over 100 public health staff on best practices for implementing health equity. As part of its Healthcare Workforce Business Unit, Syra Health Won a contract with Osawatomie State Hospital and Adair Acute Care in Kansas, to deploy licensed healthcare professionals to deliver vital social and therapy services. Secured contracts across Oklahoma, Virginia, and Alabama to deliver healthcare staffing solutions to correctional facilities. Provides on-demand temporary medical personnel, including nurses and nurses' aides, for two veteran homes in Ohio and one in Indiana. Delivers direct care staffing for the Department of Health and Human Resources Purchasing Division in the state of West Virginia. Expanded its Healthcare Workforce Solutions to include a new technology platform for employers and those seeking new positions, plus engagement and concierge services. Syra Health Announced its Expansion into Federal Government Contracts, making Federal Government Solutions the Company's Sixth Business Unit Syra Health expanded its reach beyond state and local governments to include supplying its products and services to the federal government. Milestones On September 29, 2023, Syra Health became a publicly traded company on the Nasdaq, under the ticker symbol "SYRA. In October 2023, Syra Health successfully closed on $6.7 million in IPO financing. Syra Health's third-quarter revenue increased by 4%. Importantly, the Company saw a significant rise in gross profit margins from 27.3% to 35.1% versus the same period the year prior. "2023 was a transformative year for Syra Health," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "We are incredibly proud of our team's commitment which has enabled us to secure new contracts and launch innovative products. As we step into the new year, we are driven by a profound commitment to continue addressing the most significant healthcare challenges and to improving healthcare for all." About Syra Health Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government.

Read More

Healthtech Security

Belong Health Launches Belong Medical Group to Help Health Plans and Healthcare Providers Address Gaps in Patient Care

Belong Health | January 10, 2024

Belong Health, a company dedicated to advancing patient-centered healthcare and reducing the cost of caring for underserved and complex populations, has announced the formation of Belong Medical Group to help its plan and provider partners address chronic gaps in patient care. Belong Medical Group supplements existing care infrastructure with virtual and community-based resources to care for every member – even those that are historically hard to reach. The team includes operators, clinicians, registered nurses, licensed clinical social workers and community health workers with extensive experience serving high-needs populations. Operating as a separate unit within Belong Health, Belong Medical Group is a transitional care organization that develops clinical programming and wraparound services to help plan partners, providers and provider groups care for members with chronic conditions during changes in their care plans. This improves patient outcomes while reducing overall costs. Bridging Gaps in Care Dual-eligible members require more specialty care, particularly in the areas of behavioral health and palliative care. Patients with mental illness combined with one or more chronic conditions average three-times the medical spend compared to patients without mental illness. Almost 45% of dual-eligible patients fall into this category. Belong Medical Group was built to serve high-needs patients, including the 11 million D-SNP members with complex issues, low incomes and pre-existing conditions, to improve outcomes and reduce costs. "The clinician shortage in the U.S. continues to worsen and existing care delivery models fail to meet the needs of patients, particularly those that are dually eligible,” said Belong Health CEO J. Patrick Foley. “Belong Medical Group is an innovative new model of care delivery that ensures the full integration of services, reduces fragmented care and drives operational efficiencies.” By providing transitional care, Belong Medical Group helps plans serving D-SNP beneficiaries and providers participating in ACO REACH by Bridging gaps in care through home-based and virtual specialty care services delivered by trusted members of Belong Medical Group’s Clinician and Care Management team. Ensuring equitable access to care in urban and rural areas by meeting patients where they are. Seamlessly integrating with the provider community to ensure that care is coordinated with their local provider for longitudinal care. Mental Health Connector Mental Health Connector is the first clinical solution available through Belong Medical Group. It serves patients without a current mental health provider or those with worsening chronic mental illness. These patients are identified during health risk assessments or hospital and ER admissions as having unmet mental health needs that require follow up. MVP Health Care, a regional not-for-profit health insurer serving New York and Vermont, is the first to offer Mental Health Connector to its members. "Since the inception of our pilot program with Belong Medical Group, we have witnessed notable improvements in the depression scores of our members who have sought care from our dedicated Mental Health Connector clinicians,” said Dr. Carl Cameron, MVP Health Care’s Chief Medical Officer. “This heartening progress reinforces our belief that collaborative efforts can truly shape a brighter future for those with diverse health care needs. Belong Health and Belong Medical Group stand as trusted partners who share our unwavering dedication to providing high-quality care to a complex population. We value their expertise and their commitment to working hand-in-hand with us, ensuring that our members receive the comprehensive support they need.” Patients enrolled in Mental Health Connector receive treatment from Belong Medical Group's clinicians for up to 90 days. The treatment plan put in place by Belong Medical Group’s psychiatrist or mental health specialist is then transitioned to either the patient's PCP for ongoing management, or to a longitudinal mental health clinician in the community. The goal is to both diagnose and address unmet mental health needs when patients need it most and then to triage the right level of care for the patient long-term once the issues are stabilized. This bridge to longitudinal care not only reduces the cost of care, it improves quality scores. “These programs are essential. We need to meet patients where they are to help them better stick to their care plans during transitional phases,” said Dr. Ramon Jacobs-Shaw, President of Belong Medical Group and Chief Clinical Officer at Belong Health. “Too many people, especially seniors and dually eligible individuals, have needs that are not met by the existing care delivery landscape. Belong Medical Group provides smarter and more targeted services to those patients to make sure their needs are fulfilled, improving outcomes and overall community health.” About Belong Health Belong Health provides a new approach to health insurance by establishing deep partnerships with providers and insurers. This innovative model empowers us to address the unfulfilled requirements of underserved and complex needs populations in a more patient-centric way. Through fully risk-bearing partnerships, Belong Health helps insurers deliver products that provide more collaborative care to the MA and D-SNP population. Belong Health is also an accredited Accountable Care Organization, dedicated to delivering value-based care for Medicare FFS. Our mission is to offer more compassionate, collaborative and smarter healthcare solutions for underserved and complex needs populations.

Read More